CC BY-NC-ND 4.0 · Exp Clin Endocrinol Diabetes
DOI: 10.1055/a-1608-0345
Article

Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients

Lijun Gao
1  Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Hong Huang
1  Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Lu Zhang
1  Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Ningjing Zhang
1  Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Yuzhe Fu
1  Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Dalong Zhu
1  Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
Yan Bi
1  Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
,
1  Department of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China
› Author Affiliations
Funding This study was supported by grants from the National Natural Science Foundation of China (81970704, 81970689, 81900787, 81800752, and 81800719), National Key Research and Development Program of China (2016YFC1304804 and 2017YFC1309605), Jiangsu Provincial Key Medical Discipline (ZDXKB2016012), Key Project of Nanjing Clinical Medical Science, Key Research and Development Program of Jiangsu Province of China (BE2015604 and BE2016606), Medical and Health Research Projects of Nanjing in Jiangsu Province of China (YKK18067), Project of Standardised Diagnosis and Treatment of Key Diseases in Jiangsu Province of China (2015604), and Natural Science Foundation of Jiangsu Province of China (BK20201115). Drum Tower Hospital (affiliated with Nanjing University Medical School, China) provided sponsorship for article processing charges.

Abstract

Purpose We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic.

Patients and Methods Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights.

Results A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2–6.9 kg; P<0.01)]. In the beinaglutide group, 90.6 and 40.6% of the patients lost≥5 and≥10% of their body weight, respectively, whereas, in the metformin group, these rates were 46.9 and 12.5%, respectively (P<0.01 and P<0.05). Weight loss following beinaglutide treatment mainly resulted from the loss of fat mass. Compared to metformin, beinaglutide induced a greater decrease in the body mass index, weight circumference, percent body fat, and body fat mass (total, trunk, limb, android, and gynoid). Additionally, beinaglutide decreased serum insulin levels and ameliorated insulin resistance.

Conclusions Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.

Supplementary Material



Publication History

Received: 02 March 2021
Received: 27 July 2021

Accepted: 10 August 2021

Publication Date:
02 December 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany